ADVERTISEMENT
ADVERTISEMENT

Industry Briefs

From Q To GLQ223 Eight months after the FDA stopped a San Francisco group from giving an unauthorized drug called Compound Q to HIV-infected patients, another version of the drug will be dispensed to the same patients - this time by a pharmaceutical company and a biotechnology company now clinically testing the compound. Derived from a plant protein imported from China, Compound Q had been offered in 1988 and 1989 to between 80 and 100 patients by Project Inform, an AIDS advocacy group. Genelab

The Scientist Staff

From Q To GLQ223
Eight months after the FDA stopped a San Francisco group from giving an unauthorized drug called Compound Q to HIV-infected patients, another version of the drug will be dispensed to the same patients - this time by a pharmaceutical company and a biotechnology company now clinically testing the compound. Derived from a plant protein imported from China, Compound Q had been offered in 1988 and 1989 to between 80 and 100 patients by Project Inform, an AIDS advocacy group. Genelabs Inc., a Redwood City, Calif.-based biotech firm, holds the rights to a purified form of the compound, which it has patented for possible use as an AIDS drug under the trademark GLQ223. Sandoz Ltd., of Basel, Switzerland, owns its worldwide marketing rights. Genelabs is offering the drug free to Project Inform's previous Compound Q patients, and Sandoz is giving the organization $250,000 to defray the project's...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT